Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Orelabrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AngioDynamic Receive FDA Clearance for NanoKnife Prostate Ablation
    AngioDynamic Receive FDA Clearance for NanoKnife Prostate Ablation

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241209958174/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    InnoCare Presents Orelabrutinib Data at ASH 2024
    InnoCare Presents Orelabrutinib Data at ASH 2024

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241209933281/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    InnoCare's Orelabrutinib Data Presented At ESMO Congress 2024
    InnoCare's Orelabrutinib Data Presented At ESMO Congress 2024

    13 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913406407/en

    BUSINESSWIRE
    13 Sep 2024
    Share Share
    InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib
    InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib

    12 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240312903691/en

    BUSINESSWIRE
    12 Mar 2024
    Share Share
    InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib
    InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib

    26 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231026397005/en

    BUSINESSWIRE
    26 Oct 2023
    Share Share
    Study Result of Orelabrutinib in Patients with r/r MZL Published
    Study Result of Orelabrutinib in Patients with r/r MZL Published

    12 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230912051988/en

    BUSINESSWIRE
    12 Sep 2023
    Share Share